Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Cartesian Therapeutics, Inc. (RNAC)
Company Research
Source: Yahoo! Finance
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced the appointment of Kemal Malik, MBBS to its Board of Directors. Dr. Malik brings to Cartesian over 30 years of global development, regulatory, and commercial expertise at leading pharmaceutical organizations. "We are thrilled to welcome Dr. Malik, a proven leader and industry veteran, to our Board of Directors,” said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. “His deep experience in successfully advancing innovative therapies through all stages of drug development and ultimately delivering them to patients will be invaluable as we progress our pipeline of mRNA cell therapies for treating autoimmune diseases. We look forward to leveraging his insights and counsel as we strive to expand the reach of cell therapy to autoimmunity.” “C
Show less
Read more
Impact Snapshot
Event Time:
RNAC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNAC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNAC alerts
High impacting Cartesian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RNAC
News
- Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates [Yahoo! Finance]Yahoo! Finance
- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its price target lowered by analysts at HC Wainwright from $54.00 to $49.00. They now have a "buy" rating on the stock.MarketBeat
- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its price target raised by analysts at Canaccord Genuity Group Inc. from $38.00 to $43.00. They now have a "buy" rating on the stock.MarketBeat
- Cartesian reports positive results from Phase IIb myasthenia gravis trial [Yahoo! Finance]Yahoo! Finance
- Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal MalikGlobeNewswire
RNAC
Earnings
- 5/8/24 - Miss
RNAC
Sec Filings
- 7/5/24 - Form SC
- 7/5/24 - Form 4
- 7/3/24 - Form 4
- RNAC's page on the SEC website